Evidence map›Paper›PMID 34012461›Full record

ReviewFrontiers in genetics2021

A Timely Review of Cross-Kingdom Regulation of Plant-Derived MicroRNAs.

Dan Li, Jianhui Yang, Yong Yang, Jianxin Liu, Hui Li, Rongfei Li, Chunya Cao, Liping Shi, Weihua Wu, Kai He

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Translational cancer research · 2026
    Article
  5. Review
  6. Human miRNAs in Cancer: Statistical Trends and Cross Kingdom Approach.International journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. miR395e fromGenes · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Materials today. Bio · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dan LiSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Jianhui YangSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Yong YangSchool of Pharmacy, Hunan University of Traditional Chinese Medicine, Changsha, China.
Jianxin LiuSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Hui LiSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Rongfei LiSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Chunya CaoSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Liping ShiSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Weihua WuSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Kai HeSchool of Pharmaceutical Science, Hunan University of Medicine, Huaihua, China.
Hunan University · CNHua Medicine (China) · CNHunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) belong to a class of non-coding RNAs that suppress gene expression by complementary oligonucleotide binding to the sites in target messenger RNAs. Numerous studies have demonstrated that miRNAs play crucial role in virtually all cellular processes of both plants and animals, such as cell growth, cell division, differentiation, proliferation and apoptosis. The study of rice MIR168a has demonstrated for the first time that exogenous plant MIR168a influences cholesterol transport in mice by inhibiting low-density lipoprotein receptor adapter protein 1 expression. Inspired by this finding, the cross-kingdom regulation of plant-derived miRNAs has drawn a lot of attention because of its capability to provide novel therapeutic agents in the treatment of miRNA deregulation-related diseases. Notably, unlike mRNA, some plant miRNAs are robust because of their 3' end modification, high G, C content, and the protection by microvesicles, miRNAs protein cofactors or plant ingredients. The stability of these small molecules guarantees the reliability of plant miRNAs in clinical application. Although the function of endogenous miRNAs has been widely investigated, the cross-kingdom regulation of plant-derived miRNAs is still in its infancy. Herein, this review summarizes the current knowledge regarding the anti-virus, anti-tumor, anti-inflammatory, anti-apoptosis, immune modulation, and intestinal function regulation effects of plant-derived miRNAs in mammals. It is expected that exploring the versatile role of plant-derived miRNAs may lay the foundation for further study and application of these newly recognized, non-toxic, and inexpensive plant active ingredients.

Indexed as

activitycross-kingdom regulationgene expressionmicroRNAplant

Identifiers

PMID34012461
PMCPMC8126714
OpenAlexW3157658553

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.